Join Nasus Pharma for a virtual key opinion leader (KOL) event featuring Michael S. Blaiss, MD (Medical College of Georgia, Good Samaritan Health Center of Gwinnett) and Joel Brooks, DO, MPH (Columbia University Vagelos College of Physicians and Surgeons, New York-Presbyterian Morgan Stanley Children’s Hospital), who will join company management to discuss the unmet need and current treatment landscape for anaphylaxis.

The event will provide an overview of Nasus Pharma and NS002, the Company’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. The current standard of care for anaphylaxis is the EpiPen^® injection. KOLs will review NS002’s Phase 2 data showing faster and higher absorption than the EpiPen^®, demonstrating that NS002 is poised to transform the epinephrine landscape. They will also discuss the challenges of pediatric patients, and the perspectives of practicing physicians on the need for needle-free Epinephrine.

A live question and answer session will follow the formal presentations.